Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

Lignende værker

• Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study
  af: Iwata, Hiroji, et al.
  Udgivet: (2013)
• Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer
  af: Tamura, Kenji, et al.
  Udgivet: (2017)
• Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study
  af: Watanabe, Toru, et al.
  Udgivet: (2017)
• Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial
  af: Masuda, N., et al.
  Udgivet: (2018)
• Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
  af: Ueno, Takayuki, et al.
  Udgivet: (2019)